2 Groups model FDA [Two-Stage / GS Designs]

posted by d_labes  – Berlin, Germany, 2013-04-17 13:10 (2831 d 06:42 ago) – Posting: # 10427
Views: 37,026

Gents!

» » But honestly, group x treatment?? I'd rather not go down that road. I hope you do not make precedence.
»
» Not my invention. See this post for the reference.

I have another 'better' one (from a Letter of FDA, Barbara M. Davit)! :cool:

" ... the following statistical model should be used when analyzing data from a multiple group bioequivalence study:

Group
Sequence
Treatment
Subject(nested within Group*Sequence)
Period(nested within Group)
Group-by-Sequence Interaction (sic!)
Group-by-Treatment Interaction


Subject(nested within Group*Sequence) is a random effect and all other factors are fixed effects. ..."

Enormous effect(s) :-D.

BTW: Helmut, how had you planned the evaluation of the second stage, if it would be necessary?

BTW2: In context of a 2-Stage design, also a 2-group design with groups here called stage, the mighty oracle prohibit us the Group-by-Treatment Interaction! From the EMA Q&A Rev.7 :
"Conclusion ... A term for a formulation*stage interaction should not be fitted."

BTW3: NOL = no objection letter ?

Regards,

Detlew

Complete thread:

Activity
 Admin contact
21,303 posts in 4,441 threads, 1,487 registered users;
online 8 (0 registered, 8 guests [including 5 identified bots]).
Forum time: Saturday 18:53 CET (Europe/Vienna)

If you can’t solve a problem, then there is an easier problem
you can solve: find it.    George Pólya

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5